scholarly journals P3.15-21 Real-World Experience of First-Line Afatinib Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer

2018 ◽  
Vol 13 (10) ◽  
pp. S998-S999 ◽  
Author(s):  
C. Liam ◽  
G. Ho ◽  
C. Chai ◽  
A. Bt Alip ◽  
Y. Pang
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Egfr Mutant

scholarly journals First‐Line Osimertinib in Patients with EGFR‐Mutant Advanced Non‐Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

2021 ◽  
Author(s):  
Martina Lorenzi ◽  
Alessandra Ferro ◽  
Fabiana Cecere ◽  
Daniela Scattolin ◽  
Alessandro Del Conte ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
The Real ◽  
Cancer Outcome ◽  
Egfr Mutant

scholarly journals Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer

2019 ◽  
Vol 36 (6) ◽  
Author(s):  
Hisashi Tanaka ◽  
Kageaki Taima ◽  
Masamichi Itoga ◽  
Yoshiko Ishioka ◽  
Keisuke Baba ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Egfr Mutant

Real world study of afatinib in first-line or re-challenge setting for patients with EGFR mutant non-small cell lung cancer.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e21173-e21173
Author(s):  
Hisashi Tanaka ◽  
Kageaki Taima ◽  
Masamichi Itoga ◽  
Yoshiko Ishioka ◽  
Keisuke Baba ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Egfr Mutant
Sign in / Sign up

Export Citation Format

Share Document